Item 7.01 Regulation FD Disclosure

Elanco Releases Information Confirming Seresto Flea and Tick Collar's Strong Safety Profile

· Case Does Not Equal Cause: In This Document, the Company Publicly Releases

Third-Party Reviewed Data Analysis Concluding No Evidence of a Causal Link

Between the Active Ingredients in Seresto and Pet Deaths

· Contrary to Media Reports, Active Ingredients in Seresto Extensively Studied

Together

· Survey Indicates Consumer, Veterinarian Confidence in Seresto Remains High

· Company Continues to Engage with EPA and House Subcommittee to Provide

Comprehensive Data

· Amid Misleading Media Stories, Company Driving Transparency to Ensure Consumers


   Understand Seresto's Strong Safety Profile




Greenfield, Ind. (May 7, 2021) - Elanco Animal Health, Inc. (NYSE: ELAN) today
is publicly providing data and information in this document recently shared with
the Environmental Protection Agency ("EPA") and the United States House of
Representatives Subcommittee on Economic and Consumer Policy (the
"subcommittee"), as well as a new third-party assessment, to correct
misinformation spread through some media reports regarding its Seresto flea and
tick collar. The comprehensively reviewed adverse event data further
demonstrates why the product's strong safety profile has earned registration
from more than 80 regulatory bodies around the world and the trust of pet owners
who have purchased more than 75 million collars globally to protect their pets
from fleas and ticks.



"As pet owners ourselves and a company full of people who understand the unique
bond our customers share with their pets, everyone at Elanco works tirelessly to
make high-quality, safe, and effective medicines - and we are greatly concerned
anytime someone believes they have had a negative experience with one of our
products," said Jeff Simmons, president and chief executive officer at Elanco.
"I can say with great conviction Seresto has a strong safety profile that
protects millions of dogs and cats against potentially harmful fleas and ticks,
which can transmit dangerous disease and impact pets' quality of life. I believe
it is important to publicly release data Elanco shared directly with regulators
and legislators and a new third-party assessment to help bring clarity to the
misinformation in the media."

Data Analysis Concludes No Scientific Evidence of a Causal Link in Seresto's Active Ingredients and Pet Deaths





Elanco takes product stewardship and safety seriously and intentionally casts a
wide net in gathering safety and efficacy data from pet owners and veterinarians
when products go to market. Once a report is made, a medically trained team
investigates each report to better assess and understand its cause. Elanco's
team of experts trained in the science of pharmacovigilance thoroughly review
and analyze the report data on an ongoing basis, along with reviews from outside
experts and regulatory authorities. Data are periodically monitored for signals
or trends to determine any concerns that need further evaluation.



Since Seresto's launch in 2012 through 2020, more than 28.5 million collars have
been distributed across the U.S. Over this period, 12 pets-or 0.000042%- have
reportedly died in a manner probably or possibly causally related to the Seresto
collar. None of these were linked to the active ingredients in Seresto.



In the U.S., from product launch through the end of 2020, 1,852 reports were
recorded where the Seresto collar was mentioned alongside the death of a pet.
Consistent with the standard pharmacovigilance process, each event was
investigated and assessed according to the ABON system, a recognized method of
harmonizing causality assessments for adverse events to veterinary medicinal
products.1 Using this assessment outlined below, the following information
details the 12 cases determined to be Probable (A) and Possible (B). The balance
of the remaining reports were assessed to be in the O, N, and NA categories.



ABON System:

A = Probable - it is deemed probable that the product is causally related to the reported event

B = Possible - it is deemed possible that the product is causally related to the reported event

O = Unclassifiable/Not assessable - there is not enough information available to discern a causal relationship

N = Unlikely - it is deemed unlikely that the product is causally related to the reported event

NA = No Assessment - no assessment was completed as in cases of reported events that were nullified or for those involving a confirmed counterfeit product







1 Guideline on Harmonising the Approach to Causality Assessment for Adverse
Reactions to Veterinarian Medicinal Products, Committee for Veterinary Medical
Products, The European Agency for the Evaluation of Medicinal Products, (2004)
https://www.ema.europa.eu/en/documents/scientific-guideline/guidelineharmonising-approach-causality-assessment-adverse-reactions-veterinary-medicinal-products_en.pdf


  2






        ABON Code         Number of Reports                Analysis
A - Probable                      5         ·   The result of entrapment concerning
                                            external structures, where the collar
                                            caught on an object and resulted in
                                            harm to the animal.
B - Possible                      7         ·   Five cases were determined to be
                                            oral entrapments, where the collar got
                                            caught in the jaws of the animal
                                            resulting in harm.
                                            ·   Two consisted of a case of a
                                            tightened but not entrapped collar for
                                            one dog and a case of hypersalivation,
                                            seizure and death for another dog as
                                            reported by the owner, but without any
                                            summary from an attending veterinarian.




A third-party assessment of the 12 cases was also performed by toxicology,
pathology, and veterinary pharmacovigilance expert Dr. Kevin Woodward, principal
consultant at KNW Animal Health Consulting and Fellow Chartered Chemist of the
Royal Society of Chemistry. Dr. Woodward's findings concur with Elanco's
assessment, noting two cases where Elanco assessments were more conservative
than his own assessment. Further, Dr. Woodward concluded that 11 out of 12
incidents were physical in nature and not related to the active ingredients of
Seresto, adding that these numbers are in-line with similar incidents for
non-medicated collars. In the remaining report, there is insufficient evidence
to support a causal link between the incident and the active ingredients or
other components in Seresto.



Every employee at Elanco understands the significant loss these pet owners feel
and is deeply disappointed when an adverse event or reaction associated with any
product occurs. Elanco continues to carefully monitor and analyze the data, as
well as all other incident reports it receives.

The Active Ingredients in Seresto Were Studied Extensively and Together





Contrary to false media reports, the active ingredients in Seresto collars -
flumethrin and imidacloprid - have been widely studied together, as required by
the regulatory process in the U.S. and around the world.



In initial safety testing of Seresto collars to gain EPA approval, doses of 5x
the recommended unit dosage were given to different animals for up to the
eight-month application period. The only treatment-related side effects were
mechanically induced hair thinning from collars rubbing the neck, mostly in
animals that wore multiple collars. These side effects were resolved without
therapy. Further, when applied per product label, the systemic levels of the
active ingredients remain well below the No Observed Adverse Effect Level
(NOAEL). This is well below any systemic exposure reasonably expected to cause
systemic toxic effects.



The combination of flumethrin and imidacloprid specifically enables protection
against a broad range of ectoparasites (parasites that live on the skin as
opposed to within the body). Flumethrin is an acaricidal active ingredient,
which means it targets arachnids such as ticks and mites. Imidacloprid is an
insecticidal active ingredient, which means it targets insects such as fleas and
lice. Together, these active ingredients provide protection against ticks,
fleas, lice, and other ectoparasites, which can be vectors for disease,
potentially leading to sickness and even death in pets, or in humans through
zoonotic transmission.



Proper protection for pets will be especially critical during 2021, as
forecasters predict that most states in the U.S. will experience warmer, wetter
conditions that drive increased tick populations, likely putting ticks in range
of people for much longer than in an average year.

Elanco Providing Comprehensive Data to the EPA

In the U.S., EPA conducts registration review on all registered pesticides, including the active ingredients in Seresto.





In accordance with regulatory requirements, Elanco provides reported incident
data to the EPA on a regular basis, the EPA analyzes the data, and periodically
reviews the data with Elanco. The company also analyzes incident data itself,
continually monitoring for possible signals or trends. If a trend or signal is
identified, Elanco investigates to determine if there is a causal link with the
product and if so, takes appropriate action, including engaging with regulatory
authorities. As part of this work, Elanco has from time-to-time engaged
third-party pharmacovigilance and toxicological experts to independently review
the data and compare the findings to the company's analysis. This robust review
- by the EPA, by Elanco and by third-party experts -validates the product's
safety profile.



  3






Since Seresto's U.S. regulatory approval in 2012, data have been shared with EPA
as required by regulation on the safety profile and efficacy of the product.
Each time, case data was found to support the on-going use of Seresto. This has
also been concluded by two independent analyses, supporting the positive
benefit-risk balance. Furthermore, the number and rate of incident and death
reports are not unique for Seresto and are in-line with other antiparasitic
active ingredients.



Over the past few weeks, Elanco has held in-depth discussions with a broad team
at the EPA to review reporting and data analysis on the safety profile of
Seresto. Elanco has and will continue to provide a summary of Elanco
pharmacovigilance processes, in-depth case information, causality assessments,
qualitative and quantitative evaluations of the case information, as well as
supporting data and information utilized in these analyses. Elanco will also
provide its recently conducted expert reports based upon independent analysis of
the data.

Additionally, as a globally marketed product, more than 80 other regulatory authorities around the world have reviewed the safety data collected over the course of Seresto's development prior to registration. Many regulatory authorities also require post-approval monitoring and pharmacovigilance reporting. All reviews to-date have indicated that the benefit-risk balance remains positive for Seresto.

Data Provided to Chairman of House Subcommittee on Economic and Consumer Policy



In March, the company received a letter from U.S. Rep. Raja Krishnamoorthi,
chairman of the House Subcommittee on Economic and Consumer Policy, requesting
the production of certain documents and information in connection with the
Seresto collar. With a shared interest in protecting the health and well-being
of pets and their owners, Elanco shared information with the subcommittee to set
the record straight in the face of incorrect media reports. The company provided
a summary of the safety data cited above, its pharmacovigilance process, and the
regulatory framework behind the product by the requested March 31 deadline.
Elanco continues to actively cooperate with the subcommittee to fulfill its
request for information.

Research Shows Veterinarians and Consumers Remain Confident in Seresto



In light of misinformation about Seresto, Elanco launched market research to
assess veterinarian and consumer confidence in the product to find the best ways
to provide pet owners with correct and accurate information on Seresto's safety
profile.



Of the 1,500 U.S. pet owners surveyed the week of April 23, 2021, 98 percent of
Seresto users surveyed said they intend to repurchase the product. 97 percent of
flea and tick category users surveyed could not recall negative Seresto news
over the prior four weeks.



A similar representative national sample of 246 veterinarians found that while
about half of veterinarians are familiar with the negative press coverage of
Seresto, their reported use of the product and intent to recommend has not
considerably changed.

Elanco has taken steps to ensure consumers understand Seresto's strong safety profile, including:

· Sharing additional education and accurate information through social and

traditional media channels to 20,000 veterinary clinics

· Implementing enhanced in-store and online retailer advertising and accelerated

marketing efforts to convey Seresto's strong safety profile

· Offering hands-on educational and training opportunities for up to 90,000 U.S.

in-store retail associates

· Conducting outreach to veterinary and toxicology associations to share accurate

product data

· Sharing Seresto safety profile and facts within targeted social and online


   channels

Importantly, Seresto remains available to consumers in all channels and at authorized retailers.

The Facts Support Seresto's Strong Safety Profile



As a global leader in animal health, Elanco understands and recognizes the deep
bond that pet owners share with their pets, and will continue to work tirelessly
toward the constant goal of enhancing and extending pets' quality of life
through high-quality, safe medicines. As with all of Elanco's products, the
company will continue to take actions to ensure the strong safety profile of the
Seresto collar.



About Elanco

Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal
health dedicated to innovating and delivering products and services to prevent
and treat disease in farm animals and pets, creating value for farmers, pet
owners, veterinarians, stakeholders, and society as a whole. With nearly 70
years of animal health heritage, we are committed to helping our customers
improve the health of animals in their care, while also making a meaningful
impact on our local and global communities. At Elanco, we are driven by our
vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™
ESG/Sustainability framework - all to advance the health of animals, people and
the planet. Learn more at www.elanco.com.



  4






Forward Looking Statements



This filing may include certain statements concerning expectations for the
future that are forward-looking statements as defined by federal securities law,
including statements relating to the safety of Elanco's products, status of
their regulatory approvals, actions to be taken by Elanco with regulatory
agencies, and expected consumer and veterinarian behavior. Such forward-looking
statements are subject to a variety of known and unknown risks, uncertainties,
and other factors that are difficult to predict and many of which are beyond
management's control. In particular, the expectations could be affected by,
among other things, the uncertainties inherent in research relating to product
safety and additional analyses of existing safety data, actions by regulatory
bodies, including as a result of their interpretation of studies on product
safety, unfavorable publicity resulting from media reports on our products,
public acceptance of our products, and other risks and assumptions that are
described in Elanco's annual reports on Form 10-K and other reports that are
available from the U.S. Securities and Exchange Commission. Readers are
cautioned not to place undue reliance on forward-looking statements, which
reflect management's view only as of the date made. We undertake no obligation
to update any forward-looking statement, except as otherwise required by law.



The information in this Form 8-K is being furnished and shall not be deemed
"filed" for the purposes of Section 18 of the Securities Exchange Act of 1934,
as amended ("Exchange Act"), or otherwise subject to the liabilities of that
Section and shall not be incorporated by reference into any registration
statement or other document pursuant to the Securities Act of 1933, as amended,
or the Exchange Act, except as otherwise expressly stated in such filing.

© Edgar Online, source Glimpses